A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs BMS 986166 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 21 Nov 2017 Status changed from active, no longer recruiting to completed.
- 01 Nov 2017 Planned End Date changed from 27 Oct 2017 to 7 Nov 2017.
- 01 Nov 2017 Planned primary completion date changed from 26 Oct 2017 to 7 Nov 2017.